Tags

Type your tag names separated by a space and hit enter

Assessment of metabolic control in patients with diabetes treated with insulin using Contour USB and A1cNow+ devices (COMET study).
Endocrinol Nutr. 2015 Oct; 62(8):384-90.EN

Abstract

OBJECTIVES

The self-determination of blood glucose is relevant for diabetes mellitus (DM) insulin-treated patients. The use of glucometers with advanced features and measuring glycated haemoglobin (HbA1c) may help improve metabolic control. The main objective of this study was to determine the percentage of insulin treated patients who reduced HbA1c by at least 0.4% after 6 months of using Contour and A1CNow+.

MATERIALS AND METHODS

Observational, prospective, multicentre study in adult DM insulin treated patients, with HbA1c> 8%.

RESULTS

Of the 454 recruited patients analysed, a total of 333 were evaluable. After 6 months the HbA1c decreased (P<.05) in both groups [-0.89 (95% CI -1.01 to -0.76) and -0.98 (95% CI: -1.21 to -0.76), in type 1 and 2 DM, respectively]. An HbA1c reduction of 0.4% was observed in 73% of patients after 6 months of device use. A decrease in the number of patients with HbA1c > 8% was observed, with this reaching: 41% for all, 45% in type 1 DM, and 25% in type 2 DM. In the glycaemic profile, a reduction (P<.05) was observed in pre- and post-prandial glycaemia in both groups (-20.7±36.4 and -37.1±47.1mg/dL, respectively), with 23% pre-prandial glucose < 130mg/dL and post-prandial < 180mg/dL CONCLUSION: The use of glucometers with advanced features, and measuring glycated haemoglobin (HbA1c) may help improve metabolic control and to monitor insulin treated DM patients more closely.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

Vinagre I
Unidad de Diabetes, Endocrinología y Nutrición, Hospital Clínic i Universitari, Barcelona, España. Electronic address: ivinagre@clinic.ub.es.
Álvarez P
Bayer Hispania S.L., Barcelona, España.
García N
Bayer Hispania S.L., Barcelona, España.
Roura G
Adknoma Health Research S.L., Barcelona, España.
Conget I
Unidad de Diabetes, Endocrinología y Nutrición, Hospital Clínic i Universitari, Barcelona, España.
en representación de los investigadores del estudio Comet
No affiliation info available

MeSH

AdultAlcohol DrinkingBlood GlucoseBlood Glucose Self-MonitoringDiabetes ComplicationsDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2FastingFemaleGlycated HemoglobinHumansHypoglycemic AgentsInsulinMaleMiddle AgedObesityPostprandial PeriodProspective StudiesSmokingTreatment OutcomeYoung Adult

Pub Type(s)

Comparative Study
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't

Language

eng spa

PubMed ID

26391507

Citation

Vinagre, Irene, et al. "Assessment of Metabolic Control in Patients With Diabetes Treated With Insulin Using Contour USB and A1cNow+ Devices (COMET Study)." Endocrinologia Y Nutricion : Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, vol. 62, no. 8, 2015, pp. 384-90.
Vinagre I, Álvarez P, García N, et al. Assessment of metabolic control in patients with diabetes treated with insulin using Contour USB and A1cNow+ devices (COMET study). Endocrinol Nutr. 2015;62(8):384-90.
Vinagre, I., Álvarez, P., García, N., Roura, G., & Conget, I. (2015). Assessment of metabolic control in patients with diabetes treated with insulin using Contour USB and A1cNow+ devices (COMET study). Endocrinologia Y Nutricion : Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 62(8), 384-90. https://doi.org/10.1016/j.endonu.2015.03.011
Vinagre I, et al. Assessment of Metabolic Control in Patients With Diabetes Treated With Insulin Using Contour USB and A1cNow+ Devices (COMET Study). Endocrinol Nutr. 2015;62(8):384-90. PubMed PMID: 26391507.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Assessment of metabolic control in patients with diabetes treated with insulin using Contour USB and A1cNow+ devices (COMET study). AU - Vinagre,Irene, AU - Álvarez,Pilar, AU - García,Nicolás, AU - Roura,Guillem, AU - Conget,Ignacio, AU - ,, Y1 - 2015/09/26/ PY - 2015/02/03/received PY - 2015/03/13/revised PY - 2015/03/17/accepted PY - 2015/9/23/entrez PY - 2015/9/24/pubmed PY - 2017/4/30/medline KW - Control metabólico KW - Diabetes KW - Glycated haemoglobin KW - Hemoglobina glucosilada KW - Metabolic control SP - 384 EP - 90 JF - Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion JO - Endocrinol Nutr VL - 62 IS - 8 N2 - OBJECTIVES: The self-determination of blood glucose is relevant for diabetes mellitus (DM) insulin-treated patients. The use of glucometers with advanced features and measuring glycated haemoglobin (HbA1c) may help improve metabolic control. The main objective of this study was to determine the percentage of insulin treated patients who reduced HbA1c by at least 0.4% after 6 months of using Contour and A1CNow+. MATERIALS AND METHODS: Observational, prospective, multicentre study in adult DM insulin treated patients, with HbA1c> 8%. RESULTS: Of the 454 recruited patients analysed, a total of 333 were evaluable. After 6 months the HbA1c decreased (P<.05) in both groups [-0.89 (95% CI -1.01 to -0.76) and -0.98 (95% CI: -1.21 to -0.76), in type 1 and 2 DM, respectively]. An HbA1c reduction of 0.4% was observed in 73% of patients after 6 months of device use. A decrease in the number of patients with HbA1c > 8% was observed, with this reaching: 41% for all, 45% in type 1 DM, and 25% in type 2 DM. In the glycaemic profile, a reduction (P<.05) was observed in pre- and post-prandial glycaemia in both groups (-20.7±36.4 and -37.1±47.1mg/dL, respectively), with 23% pre-prandial glucose < 130mg/dL and post-prandial < 180mg/dL CONCLUSION: The use of glucometers with advanced features, and measuring glycated haemoglobin (HbA1c) may help improve metabolic control and to monitor insulin treated DM patients more closely. SN - 1579-2021 UR - https://www.unboundmedicine.com/medline/citation/26391507/Assessment_of_metabolic_control_in_patients_with_diabetes_treated_with_insulin_using_Contour_USB_and_A1cNow+_devices__COMET_study__ DB - PRIME DP - Unbound Medicine ER -